CTRI/2023/04/051726尚未招募1 期
A prospective, interventional, open-label, phase 1a/1b, single-center, clinical study to evaluate the safety and tolerability of NV-CoV-2 Oral Syrup and Oral Gummy (Chewable gel) for oral administration in healthy and mild to moderate COVID-19 adult human subjects.
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 72
- 试验地点
- 2
- 主要终点
- To evaluate the safety and tolerability with the initial administration of NV-CoV-2 in healthy human subjects.
研究概览
简要总结
This is a phase 1 study to assess the safety and tolerability of a new molecule in healthy subjects. In Phase 1b patients with mild to moderate COVID19 shall be enrolled to assess any indication of efficacy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Computer generated randomization
- 盲法
- Open Label
入排标准
- 年龄范围
- 18.00 Year(s) 至 60.00 Year(s)（—）
- 性别
- All
入选标准
- •Common for healthy subjects and COVID-19 patients: 1-Able to comprehend the nature and purpose of the study and willing to give written informed consent for participation in the study 2-Willing to be available for the entire study period and to comply with protocol requirements.
- •3-In the case of female subjects: a-Negative urine pregnancy test during screening and negative serum β-hCG test at check-in of each study period.
- •b-Female subjects with childbearing potential or those within their first two years of onset of menopause must either abstain from sexual intercourse or use acceptable methods of birth control for at least 15 days before 1st dose till 15 days post-last-dose/ entire study period [Acceptable birth control methods include barrier methods such as diaphragm/condom with or without spermicide or who are surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy has been performed)].
- •c-They should not be in menstruation (bleeding per vaginum) on the day of the withdrawal of blood for the purpose of the study For healthy subjects 1-Normal, healthy, adult, human subject of 18 to 60 years (both inclusive) of age.
- •2-Body mass index in the range of 18 – 30 Kg/m2 (both inclusive).
- •3-Normal haemoglobin between 12.5 to 17.5 grams per deciliter (g/dL) for men and 11 to 16 g/dL for females or as per the discretion of PI/Physician.
- •4-Normal health status as determined by medical history and physical examination by the PI/Physician at the time of screening and vital signs (blood pressure, pulse rate, respiratory rate and axillary temperature) measurements and physical examination at the time of screening as well as check-in during each study period.
- •5-With normal or clinically non-significant laboratory values as determined by hematological, biochemistry tests and urine analysis 6-With a normal or clinically non-significant 12-lead ECG.
- •7-With a negative test for Human Immunodeficiency Virus (HIV) type I/II antibodies, Hepatitis B surface antigen (HBsAg) and Hepatitis C virus (HCV) antibodies, COVID-19 RT PCR.
- •8-Non-smokers and should not have been consuming any kind of tobacco products including chewing or inhaling tobacco in the form of jarda, pan, gutkha etc, Or, In the case of smokers, they should be willing to abstain from smoking or chewing any tobacco-containing product for at least 72.00 hours prior to check-in of the first period and throughout the duration of the study till safety samples are collected at the end of the study.
- •For mild to moderate Covid-19 patients 1-Both male and female adult populations aged from 18 to 60 years will be included in the study.
- •2-Confirmed RT-PCR positive for SARS CoV-2 mild to moderate (as per WHO classification) or asymptomatic patients as determined by the principal investigator/ study physician.
- •3-Controlled Diabetes (Type 2 DM (Hb1Ac < 7) and Hypertension (Systolic BP<140 mm Hg or diastolic BP<90 mm Hg).
- •4-Patients having risk factors of hospitalization due to Covid-
- •5-Patients with BMI from ≥18 to ≤ 35 kg/m2.
排除标准
- •For healthy subjects: 1-Any medical or surgical condition, which might significantly interfere with the functioning of the gastrointestinal tract or blood-forming organs. 2-History or presence of gastric or duodenal ulcer or GI bleeding or blood in stools anytime in the past. 3-History of severe infection or major surgery in the past 6 months. 4-History of Minor surgery or fracture within the past 3 months. 5-Significant history or current evidence of malignancy or chronic.
- •infectious, cardiovascular, renal, hepatic, ophthalmic, pulmonary, neurological, metabolic (endocrine), hematological, gastrointestinal, immunological, or psychiatric diseases, or organ dysfunction. 6-Any major illness or hospitalization within 90 days prior to check-in of the first period. 7-Any other clinical condition like diarrhea or vomiting within three days prior to check-in of any period. 8-Subjects who have been on an unusual or abnormal diet, for whatever reason e.g. because of fasting due to religious reasons during four weeks before check-in of the first period and throughout the duration of the study until the post-study safety sample is collected. 9-Use of any depot injection or an implant of any drug within three months prior to check-in of the first period and throughout the duration of the study until the post-study safety sample is collected. 10-Use of any prescribed medication (including herbal medicines and vitamin supplements) within 30 days or within five half-lives of the drug, whichever is longer prior to check-in of the first period and throughout the duration of the study until the post-study safety sample is collected. 11-Use of any OTC products within 7 days or within five half-lives of the drug, whichever is longer prior to first check-in and throughout the duration of the study until the post-study safety sample is collected. 12-Use of any recreational drug or history of drug addiction. 13-Participated in any clinical investigation requiring repeated blood sampling, blood donation, or otherwise leading to blood loss of ≥300 mL in the past 90 days prior to first check-in. 14-Participated in any clinical study within the past 90 days prior to check-in. 15-Consumption of alcohol or alcoholic products within 24.00 hrs prior to check-in in each study period and throughout sampling time points. 16-Positive alcohol breath or urine screening for drug abuse tests during check-in in each study period. 17-Consumption of xanthine or its derivative containing food or beverages (e.g. chocolates, tea, coffee or cola drinks) within 48.00 hours prior to check-in in each study period and throughout sampling time points. 18-Consumption of grapefruit or its juice within 72.00 hours prior to check-in in each study period and throughout sampling time points. 19-Pregnant, lactating or nursing female subjects. 20-Female subjects using hormonal contraceptives (oral/implants). 21-History of allergy or hypersensitivity or intolerance to study drugs or its formulation excipients which, in the opinion of the PI/Physician, would compromise the safety of the subject or the study. 22-History of difficulty in the accessibility of veins in arms. 23-Evidence of an uncooperative attitude. For mild to moderate Covid-19 patients 1-If the physician as per their judgment considers the patient unsuitable for the study based on the history, nutritional status, physical appearance, or any other reason. 2-Likely need for hospital admission within 24 to 48 hrs of randomization as per the assessment of the physician. (SpO2- <94%) 3-Known hepatic & kidney disease. 4-Known patient of cardiovascular disease, including congenital and ischemic heart disease, congestive cardiac failure. 5-Uncontrolled Type 2 DM (Hb1Ac >7), Insulin-dependent DM & Uncontrolled HTN (systolic BP≥140 mm Hg or diastolic BP≥90 mm Hg. 6-Patients with BMI <18 and > 35 (Obese) Kg/m2 are not included in the study. 7-Hemoglobin < 8 g/dL. 8-Known patient of HIV or on any other anti-viral medication for a disease other than Covid-19 9-Pregnant, lactating women or nursing female subjects 10-Presence of debilitating diseases like Tuberculosis, Rheumatoid arthritis, Carcinoma, Known case of inflammatory autoimmune diseases of any kind, neurodemyelinating diseases like Multiple sclerosis, Transverse myelitis, Thyroid, adrenal, pituitary endocrine disorders, Renal failure, Inflammatory bowel disease. 11-Patients who had participated in another clinical trial within the previous 30 days. 12-Patients under immune suppressants and steroids (steroid for any other disease than Covid-19). 13-Signs and symptoms, haematological, imaging investigations showing signs of severe COVID will be excluded. 14-Any other medical conditions that are considered unsuitable for the study by the investigator. 15-The patient is not willing to give an informed consent form.
结局指标
主要结局
To evaluate the safety and tolerability with the initial administration of NV-CoV-2 in healthy human subjects.
时间窗: Baseline and end of study
-To find the maximum tolerated dose for the support of phase-2 clinical trials.
时间窗: Baseline and end of study
次要结局
- To evaluate the Pharmacokinetic (for healthy subjects only) and Pharmacodynamic nature (for Covid-19 patients only) of NV-CoV-2.(-To obtain an early measurement of drug activity in mild/moderate COVID-19 patients.)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
MEDI5752 in Japanese Patients With Advanced Solid Tumors.Advanced Solid TumorsNCT05685472AstraZeneca6
进行中（未招募）
1 期
A Phase I Study of SHR-4712 in Patients With Advanced Solid TumorsNCT06993116Guangdong Hengrui Pharmaceutical Co., Ltd15
已完成
1 期
An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients With Advanced Solid MalignanciesAdvanced Solid MalignanciesNCT05469919AstraZeneca12
已完成
1 期
A Phase 1 Study of AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast CancerER+ HER2- Advanced Breast CancerNCT04541433AstraZeneca10
招募中
1 期
A Study of OL-108 in Relapsed/Refractory Autoimmune DiseasesNCT06980597Beijing GoBroad Hospital44